We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+46.67%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$235M
Cap. Flow
-$90.5M
Cap. Flow %
-8.72%
Top 10 Hldgs %
62.46%
Holding
79
New
20
Increased
8
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$12.9M
2
NVO
Novo Nordisk
NVO
+$12.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.92M
4
HALO icon
Halozyme
HALO
+$6.5M
5
BPMC
Blueprint Medicines
BPMC
+$5.31M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$43.8M
2
SNY icon
Sanofi
SNY
+$14.2M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.3M
5
INCY icon
Incyte
INCY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 89.88%
2 Miscellaneous 10.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$7.94M 0.77%
584,108
-90,528
-13% -$1.11M
ANAB icon
27
AnaptysBio
ANAB
$1.65B
$7.16M 0.69%
97,948
+72,928
+291% +$5.03M
DERM
28
DELISTED
Dermira, Inc.
DERM
$6.55M 0.63%
483,640
-58,584
-11% -$489K
XNCR icon
29
Xencor
XNCR
$1.85B
$6.52M 0.63%
209,907
+10,225
+5% +$340K
HALO icon
30
Halozyme
HALO
$12.2B
$6.46M 0.62%
+401,329
New +$6.5M
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.43M 0.62%
124,952
+27,507
+28% +$1.19M
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$5.75M 0.55%
+71,866
New +$5.31M
HRTX icon
33
Heron Therapeutics
HRTX
$63.2M
$5.71M 0.55%
233,651
-126,062
-35% -$3.3M
SVRA icon
34
Savara
SVRA
$1.11B
$5.65M 0.54%
766,672
+12,300
+2% +$92.7K
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.56M 0.54%
65,031
-92,953
-59% -$7.72M
ICPT
36
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.02M 0.48%
44,918
-9,554
-18% -$1.04M
DCPH
37
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.98M 0.48%
214,604
-50,871
-19% -$1.33M
ORTX
38
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.94M 0.48%
27,608
+5,346
+24% +$804K
INCY icon
39
Incyte
INCY
$25.5B
$4.57M 0.44%
53,097
-135,400
-72% -$11M
KDMN
40
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.41M 0.43%
1,671,770
+20,598
+1% +$51.9K
SYBX
41
DELISTED
Synlogic
SYBX
$4.36M 0.42%
38,331
– –
AKBA icon
42
Akebia Therapeutics
AKBA
$264M
$4.23M 0.41%
+516,761
New +$3.55M
INSM icon
43
Insmed
INSM
$28.1B
$4.07M 0.39%
+140,057
New +$3.63M
PBYI icon
44
CALL
Puma Biotechnology
PBYI
$467M
$3.64M 0.35%
+93,800
New +$2.86M
FATE icon
45
Fate Therapeutics
FATE
$292M
$3.58M 0.35%
203,742
-26,071
-11% -$412K
GWPH
46
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.37M 0.32%
20,000
-10,000
-33% -$1.49M
KYNB
47
Kyntra Bio
KYNB
$32.6M
$3.21M 0.31%
2,361
-839
-26% -$1.14M
FOMX
48
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.12M 0.3%
832,293
– –
XBIT icon
49
XBiotech
XBIT
$66.5M
$2.88M 0.28%
+261,391
New +$2.12M
KALA icon
50
KALA BIO
KALA
$10.8M
$2.86M 0.28%
138
-40
-22% -$711K
1
2
3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q1 2019 Portfolio in Review

As of Q1 2019, Sofinnova Investments held 79 positions worth $1.04B, up 29% from $803M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments withdrew a net $90.5M in Q1 2019, closing 12 positions and reducing 18 holdings. Its most notable exit was Sanofi, an estimated $14.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Allergan plc worth $13M.

  • Sofinnova Investments's largest Q1 2019 buy was Allergan plc: 88,665 shares worth $13M.
  • Sofinnova Investments added most to AnaptysBio in Q1 2019, an estimated $5.03M increase.
  • Sofinnova Investments's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $43.8M.
  • Sofinnova Investments fully exited Sanofi in Q1 2019, selling an estimated $14.2M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.04B portfolio in Q1 2019.
  • Sofinnova Investments opened 20 new positions and closed 12 in Q1 2019.
  • Sofinnova Investments's portfolio value rose 29% quarter-over-quarter to $1.04B.

Based on Sofinnova Investments's 13F filing for Q1 2019, filed 15 May 2019.